Parenting a Child with Bone Marrow Failure Disease - Summer 2021 Conference
When a child is diagnosed with a bone marrow failure disease, often the focus is soley on the child's medical care.
treatment
Swapna Thota, MD
Thota, Swapna
Assistant Professor of Medicine
University of Tennessee
As a physician caring for patients with acute leukemias and related disorders, I have a sustained focus on translational research in hematologic malignancies. Genomic sequencing technology revolutionized our understanding of cancer biology. My research focuses on exploring the dynamic changes of tumor immune microenvironment with clonal evolution of myeloid malignancies. Targeting inflammaging of
Online Profile:
This is Your Brain on (Chemo) Drugs - Summer 2021 Conference
Understanding GVHD
Dr. Catherine Lee will provide a comprehensive overview of chronic and acute graft vs host disease ("GvHD") which is a complication of bone marrow transplant. While some patients have very mild GvHD, many patients have more severe and long term disease. Dr. Lee will discuss pre-transplant prevention and post-transplant management of GvHD.
Catherine Lai, MD, MPH
Lai, Catherine
Associate Professor and Physician Leader of the Leukemia Clinical Research Unit
University of Pennsylvania’s Perelman Center for Advanced Medicine
Dr. Lai's clinical expertise is in Blood and Marrow Transplantation (BMT). She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She conducts her research in the Medicine Division of Hematology/BMT at the Huntsman Cancer Center.
Online Profile:
Sandy's Long, Hard, Road
Person's Name:
Sandra Barnes
Bone Marrow Disease(s):
Content source:
Alrizomadlin (APG-115)
Alrizomadlin is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. Alrizomadlin has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction.
Lisaftoclax (APG-2575)
APG-2575 is a novel, orally administered small-molecule Bcl-2‒selective inhibitor. APG-2575 is designed to treat hematologic malignancies and solid tumors by selectively blocking antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells.
Gerard Socie, MD
Socie, Gerard
Head of Hematology
Hospital St. Louis
Online Profile:
Sioban Keel, MD
Keel, Sioban
Hematologist
Fred Hutchinson Cancer Research Center
Sioban Keel, M.D., is a board certified hematologist at SCCA and a UW associate professor of Hematology and Medicine.
Online Profile: